196 related articles for article (PubMed ID: 23758084)
1. Self-assembling, amphiphilic polymer-gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinoma.
Chitkara D; Mittal A; Behrman SW; Kumar N; Mahato RI
Bioconjug Chem; 2013 Jul; 24(7):1161-73. PubMed ID: 23758084
[TBL] [Abstract][Full Text] [Related]
2. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
3. Antitumor gemcitabine conjugated micelles from amphiphilic comb-like random copolymers.
Wang J; Zhang X; Cen Y; Lin X; Wu Q
Colloids Surf B Biointerfaces; 2016 Oct; 146():707-15. PubMed ID: 27434158
[TBL] [Abstract][Full Text] [Related]
4. Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
Karaca M; Dutta R; Ozsoy Y; Mahato RI
Mol Pharm; 2016 Jun; 13(6):1822-32. PubMed ID: 26981724
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice.
Kattel K; Mondal G; Lin F; Kumar V; Mahato RI
Mol Pharm; 2017 May; 14(5):1365-1372. PubMed ID: 27798825
[TBL] [Abstract][Full Text] [Related]
6. EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer.
Mondal G; Almawash S; Chaudhary AK; Mahato RI
Mol Pharm; 2017 Sep; 14(9):3121-3133. PubMed ID: 28719220
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer.
Mittal A; Chitkara D; Behrman SW; Mahato RI
Biomaterials; 2014 Aug; 35(25):7077-87. PubMed ID: 24836307
[TBL] [Abstract][Full Text] [Related]
8. Coadministration of Polymeric Conjugates of Docetaxel and Cyclopamine Synergistically Inhibits Orthotopic Pancreatic Cancer Growth and Metastasis.
Almawash SA; Mondal G; Mahato RI
Pharm Res; 2018 Jan; 35(1):17. PubMed ID: 29305793
[TBL] [Abstract][Full Text] [Related]
9. Stereocomplex Prodrugs of Oligo(lactic acid)
Tam YT; Huang C; Poellmann M; Kwon GS
ACS Nano; 2018 Jul; 12(7):7406-7414. PubMed ID: 29957934
[TBL] [Abstract][Full Text] [Related]
10. EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer.
Mondal G; Kumar V; Shukla SK; Singh PK; Mahato RI
Biomacromolecules; 2016 Jan; 17(1):301-13. PubMed ID: 26626700
[TBL] [Abstract][Full Text] [Related]
11. Enzyme-responsive peptide dendrimer-gemcitabine conjugate as a controlled-release drug delivery vehicle with enhanced antitumor efficacy.
Zhang C; Pan D; Li J; Hu J; Bains A; Guys N; Zhu H; Li X; Luo K; Gong Q; Gu Z
Acta Biomater; 2017 Jun; 55():153-162. PubMed ID: 28259838
[TBL] [Abstract][Full Text] [Related]
12. PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy.
Ray P; Confeld M; Borowicz P; Wang T; Mallik S; Quadir M
Colloids Surf B Biointerfaces; 2019 Feb; 174():126-135. PubMed ID: 30447521
[TBL] [Abstract][Full Text] [Related]
13. Polymeric Micelles of PEG-PLA Copolymer as a Carrier for Salinomycin Against Gemcitabine-Resistant Pancreatic Cancer.
Daman Z; Montazeri H; Azizi M; Rezaie F; Ostad SN; Amini M; Gilani K
Pharm Res; 2015 Nov; 32(11):3756-67. PubMed ID: 26228105
[TBL] [Abstract][Full Text] [Related]
14. Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine.
Wang C; Liu B; Xu X; Zhuang B; Li H; Yin J; Cong M; Xu W; Lu A
Oncotarget; 2016 Feb; 7(7):8360-72. PubMed ID: 26840019
[TBL] [Abstract][Full Text] [Related]
15. Novel Gemcitabine Conjugated Albumin Nanoparticles: a Potential Strategy to Enhance Drug Efficacy in Pancreatic Cancer Treatment.
Kushwah V; Agrawal AK; Dora CP; Mallinson D; Lamprou DA; Gupta RC; Jain S
Pharm Res; 2017 Nov; 34(11):2295-2311. PubMed ID: 28795274
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
17. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
[TBL] [Abstract][Full Text] [Related]
20. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
